These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 26024761)

  • 1. Chemically Programmed Bispecific Antibody Targeting Legumain Protease and αvβ3 Integrin Mediates Strong Antitumor Effects.
    Liu Y; Goswami RK; Liu C; Sinha SC
    Mol Pharm; 2015 Jul; 12(7):2544-50. PubMed ID: 26024761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple catalytic aldolase antibodies suitable for chemical programming.
    Goswami RK; Huang ZZ; Forsyth JS; Felding-Habermann B; Sinha SC
    Bioorg Med Chem Lett; 2009 Jul; 19(14):3821-4. PubMed ID: 19428247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemically programmed antibodies targeting multiple alpha(v) integrins and their effects on tumor-related functions in vitro.
    Goswami RK; Bajjuri KM; Forsyth JS; Das S; Hassenpflug W; Huang ZZ; Lerner RA; Felding-Habermann B; Sinha SC
    Bioconjug Chem; 2011 Aug; 22(8):1535-44. PubMed ID: 21774545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting cell surface alpha(v)beta(3) integrin increases therapeutic efficacies of a legumain protease-activated auristatin prodrug.
    Liu Y; Bajjuri KM; Liu C; Sinha SC
    Mol Pharm; 2012 Jan; 9(1):168-75. PubMed ID: 22044266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beta-lactam-based approach for the chemical programming of aldolase antibody 38C2.
    Gavrilyuk JI; Wuellner U; Barbas CF
    Bioorg Med Chem Lett; 2009 Mar; 19(5):1421-4. PubMed ID: 19181522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A T-cell-engaging B7-H4/CD3-bispecific Fab-scFv Antibody Targets Human Breast Cancer.
    Iizuka A; Nonomura C; Ashizawa T; Kondou R; Ohshima K; Sugino T; Mitsuya K; Hayashi N; Nakasu Y; Maruyama K; Yamaguchi K; Akiyama Y
    Clin Cancer Res; 2019 May; 25(9):2925-2934. PubMed ID: 30737243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An efficient chemical approach to bispecific antibodies and antibodies of high valency.
    Gavrilyuk JI; Wuellner U; Salahuddin S; Goswami RK; Sinha SC; Barbas CF
    Bioorg Med Chem Lett; 2009 Jul; 19(14):3716-20. PubMed ID: 19497743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preparation of integrin alpha(v)beta3-targeting Ab 38C2 constructs.
    Sinha SC; Das S; Li LS; Lerner RA; Barbas CF
    Nat Protoc; 2007; 2(2):449-56. PubMed ID: 17406606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and evaluation of the aldolase antibody-derived chemical-antibodies targeting α5β1 integrin.
    Goswami RK; Liu Y; Liu C; Lerner RA; Sinha SC
    Mol Pharm; 2013 Feb; 10(2):538-43. PubMed ID: 23102054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small molecule drug activity in melanoma models may be dramatically enhanced with an antibody effector.
    Popkov M; Rader C; Gonzalez B; Sinha SC; Barbas CF
    Int J Cancer; 2006 Sep; 119(5):1194-207. PubMed ID: 16570283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation and Characterization of a Bispecific Antibody Targeting Both PD-1 and c-MET.
    Wu Y; Yu M; Sun Z; Hou W; Wang Y; Yuan Q; Mo W
    Protein Pept Lett; 2018 Feb; 24(12):1105-1112. PubMed ID: 29046141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanocell targeting using engineered bispecific antibodies.
    Taylor K; Howard CB; Jones ML; Sedliarou I; MacDiarmid J; Brahmbhatt H; Munro TP; Mahler SM
    MAbs; 2015; 7(1):53-65. PubMed ID: 25523746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autocrine pro-legumain promotes breast cancer metastasis via binding to integrin αvβ3.
    Liu C; Wang J; Zheng Y; Zhu Y; Zhou Z; Liu Z; Lin C; Wan Y; Wen Y; Liu C; Yuan M; Zeng YA; Yan Z; Ge G; Chen J
    Oncogene; 2022 Aug; 41(34):4091-4103. PubMed ID: 35854065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells.
    Yu S; Zhang J; Yan Y; Yao X; Fang L; Xiong H; Liu Y; Chu Q; Zhou P; Wu K
    J Exp Clin Cancer Res; 2019 Aug; 38(1):355. PubMed ID: 31412896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Legumain Functions as a Transient TrkB Sheddase.
    Holzner C; Böttinger K; Blöchl C; Huber CG; Dahms SO; Dall E; Brandstetter H
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breaking the one antibody-one target axiom.
    Guo F; Das S; Mueller BM; Barbas CF; Lerner RA; Sinha SC
    Proc Natl Acad Sci U S A; 2006 Jul; 103(29):11009-14. PubMed ID: 16822849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A heterodimeric Fc-based bispecific antibody simultaneously targeting VEGFR-2 and Met exhibits potent antitumor activity.
    Choi HJ; Kim YJ; Lee S; Kim YS
    Mol Cancer Ther; 2013 Dec; 12(12):2748-59. PubMed ID: 24132142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Esomeprazole inhibits the lysosomal cysteine protease legumain to prevent cancer metastasis.
    Zhao T; Liu Y; Hao Y; Zhang W; Tao L; Wang D; Li Y; Liu Z; McKenzie EA; Zhao Q; Diao A
    Invest New Drugs; 2021 Apr; 39(2):337-347. PubMed ID: 32978718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A humanized aldolase antibody for selective chemotherapy and adaptor immunotherapy.
    Rader C; Turner JM; Heine A; Shabat D; Sinha SC; Wilson IA; Lerner RA; Barbas CF
    J Mol Biol; 2003 Sep; 332(4):889-99. PubMed ID: 12972259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single-domain antibody-based and linker-free bispecific antibodies targeting FcγRIII induce potent antitumor activity without recruiting regulatory T cells.
    Rozan C; Cornillon A; Pétiard C; Chartier M; Behar G; Boix C; Kerfelec B; Robert B; Pèlegrin A; Chames P; Teillaud JL; Baty D
    Mol Cancer Ther; 2013 Aug; 12(8):1481-91. PubMed ID: 23757164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.